(AOF) – Abivax (-2.27% to 2.66 euros) announces the filing of a Form F-1 registration document with the US Securities and Exchange Commission (SEC) as part of its project IPO in the form of American Depositary Shares (ADS) representing common shares in the United States. The biotech specialist in modulating the immune response in patients suffering from chronic inflammatory diseases adds that a concomitant placement of its ordinary shares in Europe and other countries outside the United States has been completed.
Abivax specifies that the number of ordinary shares represented by each ADS, the number of ADSs and ordinary shares offered and the price range of the Global Offering “have not yet been determined”. The Global Offer is subject to market conditions and there can be no assurance as to whether or when the Global Offer will be completed.
The company announced its planned listing across the Atlantic in August 2023.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
